Price Chart

Key Stats

Net Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.58% -0.00% 258.42M 9416.30
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (Since Inception)
0.02% 71.00% -1.960M Upgrade

Basic Info

Investment Strategy
The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Small Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Global Category Name Healthcare Sector Equity
YCharts Categorization Healthcare Equity
YCharts Benchmark S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR)
Prospectus Objective Specialty - Health
Fund Owner Firm Name Invesco
Prospectus Benchmark Index
Dynamic Biotech&Genome Intellidex TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Peter Hubbard 16.68 yrs
Michael Jeanette 15.43 yrs
Tony Seisser 9.43 yrs
Pratik Doshi 3.43 yrs

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of February 23, 2024. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Loading chart...
Name
2017
2018
2019
2020
2021
2022
2023
YTD
22.28%
-0.19%
18.65%
25.66%
1.54%
-10.83%
3.71%
-1.89%
22.40%
-8.71%
27.67%
15.90%
21.82%
-18.14%
23.79%
5.36%
50.15%
-1.23%
34.45%
67.26%
-3.20%
-20.61%
-4.54%
12.88%
30.50%
8.91%
22.31%
32.91%
3.04%
-23.34%
-6.23%
2.77%
45.63%
-11.71%
50.30%
21.17%
-17.55%
-28.08%
8.68%
8.13%
43.77%
-15.27%
32.56%
48.33%
-20.45%
-25.87%
7.60%
6.11%
As of February 23, 2024.

Asset Allocation

As of February 22, 2024.
Type % Net % Long % Short
Cash 0.07% Upgrade Upgrade
Stock 99.93% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Basic Info

Investment Strategy
The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Small Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Global Category Name Healthcare Sector Equity
YCharts Categorization Healthcare Equity
YCharts Benchmark S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR)
Prospectus Objective Specialty - Health
Fund Owner Firm Name Invesco
Prospectus Benchmark Index
Dynamic Biotech&Genome Intellidex TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Peter Hubbard 16.68 yrs
Michael Jeanette 15.43 yrs
Tony Seisser 9.43 yrs
Pratik Doshi 3.43 yrs

Top Portfolio Holders

0 of 0